Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026 2026-08-19 14:48
Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs) 2026-07-20 16:20
Tarek Samad appointed EVP, Head of Research & Development at Lundbeck 2026-06-24 18:19
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders® 2025 2025-10-02 16:41
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan 2025-03-10 16:57
1